Details

<p>List of Contributors vii</p> <p>Preface ix</p> <p><b>Part I: Nature of the condition</b></p> <p>1 Non-alcoholic fatty liver disease: Hype or harm? 3<br /> <i>Stephen H. Caldwell and Curtis K. Argo</i></p> <p>2 NAFLD: A worldwide problem 8<br /> <i>Joanna K. Dowman Geoffrey C. Farrell and Philip Newsome</i></p> <p>3 Is insulin resistance the principal cause of NAFLD? 15<br /> <i>Ian F. Godsland Sanjeev Mehta Shareen Forbes Fabian Meienberg Michael Yee Simon D. Taylor‐Robinson and Desmond G. Johnston</i></p> <p>4 Paediatric NAFLD: A distinct disease with the propensity for progressive fibrosis 29<br /> <i>Emer Fitzpatrick and Anil Dhawan</i></p> <p>5 Non‐alcoholic fatty liver disease (NAFLD) as cause of cryptogenic cirrhosis 36<br /> <i>Jay H. Lefkowitch</i></p> <p>6 Is NAFLD different in absence of metabolic syndrome? 44<br /> <i>Yusuf Yilmaz</i></p> <p>7 Occurrence of noncirrhotic HCC in NAFLD 50<br /> <i>Dawn M. Torres and Stephen A. Harrison</i></p> <p>8 Fibrosis progression: Putative mechanisms and molecular pathways 61<br /> <i>Wing‐Kin Syn and Anna Mae Diehl</i></p> <p>9 When is it NAFLD and when is it ALD?: Can the histologic evaluation of a liver biopsy guide the clinical evaluation? 72<br /> <i>Elizabeth M. Brunt and David E. Kleiner</i><b>                                                                                                                </b></p> <p>10 Of men and microbes: Role of the intestinal microbiome in non-alcoholic fatty liver disease 82<br /> <i>Muhammad Bilal Siddiqui Mohammed Shadab Siddiqui and Arun J. Sanyal</i></p> <p>11 Can genetic influence in non‐alcoholic fatty liver disease be ignored? 91<br /> <i>Yang‐Lin Liu Christopher P. Day and Quentin M. Anstee</i></p> <p>12 Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? 103<br /> <i>Soo Lim</i></p> <p><b>Part III: Diagnosis and Scoring</b></p> <p>13 How to best diagnose NAFLD/NASH? 113<br /> <i>Vlad Ratziu</i></p> <p>14 The clinical utility of noninvasive blood tests and elastography 124<br /> <i>Emmanuel A. Tsochatzis and Massimo Pinzani</i></p> <p>15 Are the guidelines—AASLD IASL EASL and BSG—of help in the management of patients with NAFLD? 131<br /> <i>Cristina Margini and Jean‐François Dufour</i></p> <p>16 Imaging methods for screening of hepatic steatosis 138<br /> <i>Hero K. Hussain</i></p> <p>17 Are the advantages of obtaining a liver biopsy outweighed by the disadvantages? 152<br /> <i>Jeremy F. L. Cobbold and Simon D. Taylor‐Robinson</i></p> <p>18 Screening for NAFLD in high‐risk populations 161<br /> <i>Nader Lessan</i></p> <p><b>Part IV: Value of treatment measures</b></p> <p>19 Defining the role of metabolic physician 173<br /> <i>Nicholas Finer</i></p> <p>20 Should physicians be prescribing or patients self‐medicating with orlistat vitamin E vitamin D insulin sensitizers pentoxifylline or coffee? 182<br /> <i>Haripriya Maddur and Brent A. Neuschwander‐Tetri</i></p> <p>21 Effects of treatment of NAFLD on the metabolic syndrome 189<br /> <i>Hannele Yki‐Järvinen</i></p> <p>22 What are the dangers as well as the true benefits of bariatric surgery? 196<br /> <i>Andrew Jenkinson</i></p> <p>23 Liver transplantation: What can it offer? 203<br /> <i>Roger Williams</i></p> <p><b>Part V: What does the future hold?</b></p> <p>24 Molecular antagonists leptin or other hormones in supplementing environmental factors? 211<br /> <i>Jonathan M. Hazlehurst and Jeremy W. Tomlinson</i></p> <p>25 What is the role of antifibrotic therapies in the current and future management of NAFLD? 218<br /> <i>Natasha McDonald and Jonathan Fallowfield</i></p> <p>26 Developmental programming of non‐alcoholic fatty liver disease 226<br /> <i>Jiawei Li Paul Cordero and Jude A. Oben</i></p> <p>Index 232</p>

<p><b>Professor Roger Williams</b> CBE, runs the Institute of Hepatology at UCL, and is a twice former president of EASL. He has authored an incredible 2100 journal articles. Despite advancing years, he is still actively involved in clinical research -- 340 articles in the past ten years, and analysis by ISI shows him to be one of the most influential researchers in his field. The award of a CBE for services to medicine recognised his major contribution to the study of liver disorders over 25 years including leading the team who performed the first ever UK liver transplant. He also performed George Best's controversial liver transplant in 2002.<br />Prof Williams has had many awards, medals, honorary fellowships, and in 2006 was included by HRH The Queen in a celebration at Buckingham Palace to honour those who continue to contribute to public service beyond the age of 65yrs. He was made a Fellow of King's College London in 1992 and an Honorary Fellowship from UCL was conferred on him in 2008, in recognition of his distinguished career and outstanding service to UCL.</p> <p><b>Professor Simon Taylor-Robinson</b> joined the Department of Medicine at Imperial College London in 1997, having previously been Senior Registrar in Gastroenterology and Hepatology at Hammersmith Hospital. He was awarded the Sir Francis Avery Jones Gold Medal by the British Society of Gastroenterology in 1999 and the Young Investigator Award of the Liver Section of the European Gastroenterology Association in 1997. He is currently Director of the Imperial Clinical Research Facility at St Mary's Hospital, London.</p>

GB